Search - tctmd.com

Displaying 161 - 180 of 1462

Sort: Relevancy | Date

Presentation THT Abstracts 2025

Impact of LV Unloading Strategy on Clinical Outcomes of Patients Supported With VA-ECMO from the Cardiogenic Shock Working Group

Presenter: Kevin John

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Presenter: Abduljabar Adi

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

Presenter: Phuuwadith Wattanachayakul

February 11, 2025

Presentation THT 2025

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Position 1: It Should be Class IIa

Presenter: Manreet Kanwar

February 11, 2025

Presentation THT 2025

Position 2: It Should be Class I

Presenter: Navin Kapur

February 11, 2025

Presentation THT 2025

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Incidence and Outcome of Early and Late Right Ventricular Failure in Patients with the HeartMate 3 LVAD: A MOMENTUM 3 Analysis

Presenter: Gabriel Sayer

February 11, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Changes in Seated Pulmonary Artery Pressure in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Presenter: Sandip Zalawadiya

February 11, 2025

Presentation THT 2025

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

Presenter: James Udelson

February 11, 2025

Presentation THT 2025

Robotic Surgical Technique for Performing Heart Transplant

Presenter: Feras Khaliel

February 11, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Clinical Characteristics and Predictors of Mortality in Cardiogenic Shock: A PREMIER Healthcare Database Analysis

Presenter: Joseph Ibrahim

February 11, 2025

Presentation THT 2025

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Presenter: Abduljabar Adi

February 11, 2025

Presentation THT 2025

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Presenter: Anthony Carnicelli

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Advertisement

Impact of LV Unloading Strategy on Clinical Outcomes of Patients Supported With VA-ECMO from the Cardiogenic Shock Working Group

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Position 1: It Should be Class IIa

Position 2: It Should be Class I

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Incidence and Outcome of Early and Late Right Ventricular Failure in Patients with the HeartMate 3 LVAD: A MOMENTUM 3 Analysis

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Changes in Seated Pulmonary Artery Pressure in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

Robotic Surgical Technique for Performing Heart Transplant

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Clinical Characteristics and Predictors of Mortality in Cardiogenic Shock: A PREMIER Healthcare Database Analysis

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Management of Clinically Stable Patients With Impella 5.5 on a Cardiac Stepdown Unit Is Associated With Low Adverse Event Rates and Lower Hospital Costs

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content